Highlights second quarter 2025:
o Q2 revenue reached USD 55.3 million, a 12% increase year-over-year, with
adjusted EBITDA of USD 13.6 million, up 41% from the prior year.
o Human Health Ingredients delivered USD 29.2 million in revenue, up 15% YoY,
driven by continued volume growth and improved price mix. Adjusted EBITDA grew
28% to USD 13.9 million
o Consumer Health Products generated USD 27.1 million in revenue, an increase of
9% YoY, with stable gross margins and improved EBITDA margin due to good cost
control
o Emerging Business reported USD 2.1 million in revenue, stable compared to
previous quarters. EBITDA improved on lower opex following a reduction in
marketing spend.

"We continued our positive momentum in the second quarter with double-digit
revenue growth and a 41% increase in adjusted EBITDA. I am especially proud of
the Human Health Ingredients segment, reaching an EBITDA of USD 13.9 million
this quarter already. The expansion of our customer base - now larger and more
diversified than ever - played a key role in this quarter's performance.", said
Matts Johansen, CEO of Aker BioMarine.  

Human Health Ingredients continued its strong performance with 15% revenue
growth year-over-year, led by solid demand across all regions - particularly
China and Asia Pacific. Adjusted EBITDA increased significantly, supported by
improved volume, price, and lower unit costs.

Consumer Health Products delivered 9% revenue growth year-over-year. The growth
was driven by continued momentum in Sam's Club Multivitamin Gummies and Costco
Taiwan. Gross margins remained stable, while EBITDA margins improved due to good
cost control.

Outlook
The Human Health Ingredients segment sees continued year-over-year growth,
supported by good underlying demand in multiple markets. In Consumer Health
Products, the business has returned to modest growth, with revenues following
market growth. The Emerging Business segment remains on track toward cash
break-even, with active engagement in potential transactions. At the corporate
level, the company has established a new, leaner cost base and is executing on
initiatives to further improve financial and operational efficiency. 

AKBM is adapting to market trends through productivity and cost measures while
actively assessing the potential impact of increased macroeconomic uncertainty
and new tariffs.

Attached is the quarterly presentation and report for Q2. Group reported
financial figures can be downloaded in an excel from the company's investor
page: Investor - Analyst information

At 09:00 CET today, the management hosts a webcast. The webcasted presentation
will be in English. To join, please use the link that is available at
www.akerbiomarine.com/investor. 

A replay of the presentation will be made available soon after the presentation
at the same web address.

For further information, please contact 
Christopher Robin Vinter, VP Strategic Finance & IR 
Mobile: +47 911 60 820 
Email:  Christopher.vinter@akerbiomarine.com  

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, FloraMarine, and
PL+, as well as the consumer brand, Kori Krill. The innovative approach also
extends into the spin-offs AION (reduce and recycle plastic waste across
industries) and Understory (a protein brand). Aker BioMarine is listed on the
Oslo Stock Exchange (AKBM). More information is available at
www.akerbiomarine.com.